This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment.
Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.
Top Analyst Reports for Gilead Sciences, Las Vegas Sands & Illinois Tool Works
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Gilead Sciences (GILD), Las Vegas Sands (LVS) and Illinois Tool Works (ITW).
What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?
by Zacks Equity Research
Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
by Zacks Equity Research
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).
ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk
by Zacks Equity Research
On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).
Trump Attacks Biotech & Pharma: ETFs Bleed
by Sweta Killa
Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.
Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
by Zacks Equity Research
Merck (MKGAF) and Vertex (VRTX) collaborated for the development and commercialization of four research and development programs for the treatment of cancer.
Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.
by Zacks Equity Research
Mylan (MYL) and Biocon Ltd. announced that the FDA had accepted the BLA for their biosimilar version of Herceptin (trastuzumab), MYL-1401O.
Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
by Madeleine Johnson
After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.
Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA.
by Zacks Equity Research
Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study
by Zacks Equity Research
Bristol-Myers (BMY) and GeneCentric Diagnostics inked an exploratory biomarker research collaboration.
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)
by Zacks Equity Research
Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study
by Zacks Equity Research
Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.
Spark Therapeutics Gets $15M Milestone Payment from Pfizer
by Zacks Equity Research
Spark Therapeutics (ONCE) received a $15 million milestone payment from partner Pfizer Inc. (PFE) for achieving a pre-specified safety and efficacy profile in the phase I/II study on SPK-9001, which is being evaluated for the treatment of hemophilia B.
The Zacks Analyst Blog Highlights: Verizon Communications, Pfizer, Chevron, Caterpillar and ExxonMobil
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon Communications, Pfizer, Chevron, Caterpillar and ExxonMobil
Bayer's sNDA for Stivarga Granted Priority Review in the U.S.
by Zacks Equity Research
Bayer (BAYRY) announced that the FDA has granted priority review designation to its sNDA for Stivarga for the second-line treatment of patients with uHCC.
The Zacks Analyst Blog Highlights: UnitedHealth, Pfizer, Lockheed Martin, 3M and TripAdvisor
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Pfizer, Lockheed Martin, 3M and TripAdvisor
5 Dogs of the Dow Stocks for 2017
by Swarup Gupta
After a dismal 2015, during which it lost 2.3%, the Dow has just completed a spectacular year.
Inotek (ITEK) Down on Poor Phase III Glaucoma Drug Data
by Zacks Equity Research
Shares of Inotek Pharmaceuticals Corporation (ITEK) plunged 71.3% after the company announced that its lead candidate trabodenoson failed to meet the primary endpoint in a phase III trial.
4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017
by Zacks Equity Research
Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.
Mylan (MYL) Announces Multiple Generic Launches in the U.S.
by Zacks Equity Research
Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.
ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong
by Zacks Equity Research
Shares of ARIAD Pharma surged 98.4% year to date and outperformed the Zacks classified Medical-Drugs industry that declined 25.4%.
Merck (MRK) Does Well in 2016: Reasons for Outperformance
by Zacks Equity Research
Merck & Co. Inc.'s (MRK) share price is up 12.1%, so far this year.